PFIZER INC Research and Development Asset Acquired Other than Through Business Combination, Written-off
PFIZER INC (PFE) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $16.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-04
- PFIZER INC research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-28 was $16.00M, a 700.00% increase year-over-year.
- PFIZER INC research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-29 was $137.00M, a 1422.22% increase year-over-year.
- PFIZER INC research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $212.00M, a 140.91% increase year-over-year.
- PFIZER INC research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-28 was $1.39B, a 10592.31% increase year-over-year.
- PFIZER INC research and development asset acquired other than through business combination, written-off for fiscal 2025 was $1.61B, a 1393.52% increase from fiscal 2024.
- PFIZER INC research and development asset acquired other than through business combination, written-off for fiscal 2024 was $108.00M, a 44.33% decline from fiscal 2023.
- PFIZER INC research and development asset acquired other than through business combination, written-off for fiscal 2023 was $194.00M, a 79.64% decline from fiscal 2022.
- PFIZER INC research and development asset acquired other than through business combination, written-off for fiscal 2022 was $953.00M, a 72.53% decline from fiscal 2021.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2026-06-28 | $16.00M 10-Q · filed 2026-08-04 | $153.00M 10-Q · filed 2026-08-04 | $365.00M derived: sum of 3 quarters · filed 2026-08-04 | $1.75B derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-29 | $137.00M 10-Q · filed 2026-05-05 | $349.00M derived: sum of 2 quarters · filed 2026-05-05 | $1.74B derived: sum of 3 quarters · filed 2026-05-05 | $1.74B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $212.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.60B derived: sum of 2 quarters · filed 2026-02-26 | $1.60B derived: sum of 3 quarters · filed 2026-08-04 | $1.61B 10-K · filed 2026-02-26 |
| 2025-09-28 | $1.39B 10-Q · filed 2025-11-04 | $1.39B derived: sum of 2 quarters · filed 2026-08-04 | $1.40B 10-Q · filed 2025-11-04 | $1.49B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-29 | $2.00M 10-Q · filed 2026-08-04 | $11.00M 10-Q · filed 2026-08-04 | $99.00M derived: sum of 3 quarters · filed 2026-08-04 | $112.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-30 | $9.00M 10-Q · filed 2026-05-05 | $97.00M derived: sum of 2 quarters · filed 2026-05-05 | $110.00M derived: sum of 3 quarters · filed 2026-05-05 | $116.00M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $88.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $101.00M derived: sum of 2 quarters · filed 2026-02-26 | $107.00M derived: sum of 3 quarters · filed 2026-02-26 | $108.00M 10-K · filed 2026-02-26 |
| 2024-09-29 | $13.00M 10-Q · filed 2025-11-04 | $19.00M derived: sum of 2 quarters · filed 2025-11-04 | $20.00M 10-Q · filed 2025-11-04 | $91.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $6.00M 10-Q · filed 2025-08-05 | $6.00M 10-Q · filed 2025-08-05 | $78.00M derived: sum of 3 quarters · filed 2026-02-26 | $145.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | $72.00M derived: sum of 2 quarters · filed 2026-02-26 | $139.00M derived: sum of 3 quarters · filed 2026-02-26 | $172.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $72.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $139.00M derived: sum of 2 quarters · filed 2026-02-26 | $172.00M derived: sum of 3 quarters · filed 2026-02-26 | $194.00M 10-K · filed 2026-02-26 |
| 2023-10-01 | $67.00M 10-Q · filed 2024-11-04 | $100.00M derived: sum of 2 quarters · filed 2024-11-04 | $122.00M 10-Q · filed 2024-11-04 | $194.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-07-02 | $33.00M 10-Q · filed 2024-08-05 | $55.00M 10-Q · filed 2024-08-05 | $127.00M derived: sum of 3 quarters · filed 2025-02-27 | $651.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-04-02 | $21.00M 10-Q · filed 2024-05-08 | $94.00M derived: sum of 2 quarters · filed 2025-02-27 | $618.00M derived: sum of 3 quarters · filed 2025-02-27 | $619.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $73.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $597.00M derived: sum of 2 quarters · filed 2025-02-27 | $598.00M derived: sum of 3 quarters · filed 2025-02-27 | $953.00M 10-K · filed 2025-02-27 |
| 2022-10-02 | $524.00M 10-Q · filed 2023-11-08 | $525.00M derived: sum of 2 quarters · filed 2023-11-08 | $880.00M 10-Q · filed 2023-11-08 | $3.35B derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-07-03 | $1.00M 10-Q · filed 2023-08-09 | $356.00M 10-Q · filed 2023-08-09 | $2.83B derived: sum of 3 quarters · filed 2024-02-22 | $3.59B derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-04-03 | $355.00M 10-Q · filed 2023-05-10 | $2.82B derived: sum of 2 quarters · filed 2024-02-22 | $3.59B derived: sum of 3 quarters · filed 2024-02-22 | $3.81B derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $2.47B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $3.23B derived: sum of 2 quarters · filed 2024-02-22 | $3.45B derived: sum of 3 quarters · filed 2024-02-22 | $3.47B 10-K · filed 2024-02-22 |
| 2021-10-03 | $762.00M 10-Q · filed 2022-11-09 | $981.00M derived: sum of 2 quarters · filed 2022-11-09 | $1.00B 10-Q · filed 2022-11-09 | |
| 2021-07-04 | $219.00M 10-Q · filed 2022-08-10 | $238.00M 10-Q · filed 2022-08-10 | ||
| 2021-04-04 | $19.00M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $684.00M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |